Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss ... and Wegovy. Novo is now planning further trials in adults with obesity.

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

The phase Ib/IIa study evaluated the safety, tolerability, pharmacokinetics and proof-of-concept of three doses of amycretin in obesity ... contrast, Wegovy only showed a weight loss of around ...

Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.

Imagine this: You walk into your doctor and get your yearly flu vaccine and a yearly dose of your weight-loss injection. If Eli Lilly has its way, this may be the future of obesity care.

Pharmacy leaders have issued warnings about the online sale of GLP-1 weight-loss drugs, including Wegovy and Mounjaro ... it added. Obesity is one of the biggest challenges facing our country ...

A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results ... s approved obesity med Wegovy, with another engineered ...

Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...

One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their ...

Amycretin is considered as Novo Nordisk’s most competitive treatment in its weight-loss pipeline for obesity and type-2 diabetes, as the patent for its blockbuster drug Wegovy is set to expire i ...

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered ... ingredient as Ozempic and Wegovy. Novo is now planning further trials ...